Compare Illumina, Inc. (ILMN) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs SOLAI Limited — how do they compare? Illumina, Inc. trades at $190.1 (market cap $29.12B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Illumina, Inc. is far larger — about 1744.8× SOLAI Limited's market cap, and Illumina, Inc. is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ILMN | SLAI | |
|---|---|---|
Market Cap | $29.12B | $16.69M |
Sector | Health | Technology |
52-Week High | $205.10 | $26.74 |
52-Week Low | $91.00 | $2.74 |
Enterprise Value | $30.48B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Technical indicators show a bullish signal despite fundamental weakness. Recent developments include a 7:1 reverse stock split effective July 2026 and NYSE delisting proceedings initiated in July 2026 following multiple compliance notices.
Investment outlook remains highly speculative given the company's financial deterioration and exchange delisting risk. The acquisition of NEURALAND stake and Solode Neo product launch provide potential growth catalysts, but current negative profitability and cash flow challenges outweigh near-term opportunities. Analyst consensus shows 100% hold rating with no buy recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
